177Lu-DOTATATE

You have access
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
Andreas Hallqvist, Elva Brynjarsdóttir, Tomas Krantz, Marie Sjögren, Johanna Svensson and Peter Bernhardt

Journal of Nuclear Medicine May 1, 2025, 66 (5) 707-712; DOI: https://doi.org/10.2967/jnumed.124.268902
You have access
Multicycle Dosimetric Behavior and Dose–Effect Relationships in [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Gunjan Kayal, Molly E. Roseland, Chang Wang, Kellen Fitzpatrick, David Mirando, Krithika Suresh, Ka Kit Wong and Yuni K. Dewaraja

Journal of Nuclear Medicine April 24, 2025, jnumed.124.269389; DOI: https://doi.org/10.2967/jnumed.124.269389
You have access
¹⁷⁷Lu-DOTATATE Plus Capecitabine Versus ¹⁷⁷Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R. Chandekar, Chandan K. Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Jaya Shukla, Ajay Kumar and Bhagwant Rai Mittal

Journal of Nuclear Medicine February 1, 2025, 66 (2) 238-244; DOI: https://doi.org/10.2967/jnumed.124.268617
You have access
Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After ¹⁷⁷Lu-DOTATATE Therapy
Andrew F. Voter, Andrei Gafita, Rudolf A. Werner, Ana De Jesus-Acosta, Steven P. Rowe and Lilja B. Solnes

Journal of Nuclear Medicine September 1, 2024, 65 (9) 1423-1426; DOI: https://doi.org/10.2967/jnumed.124.267462
You have access
Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy
Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina Götze, Alexander von Werder, Matthias Eiber, Markus R. Makowski, Rickmer Braren and Fabian Lohöfer

Journal of Nuclear Medicine August 1, 2024, 65 (8) 1244-1249; DOI: https://doi.org/10.2967/jnumed.123.267098
You have access
Effectiveness and Safety of Retreatment with ¹⁷⁷Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States
Ebrahim S. Delpassand, Soheil M. Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang and Jeetvan Patel

Journal of Nuclear Medicine May 1, 2024, 65 (5) 746-752; DOI: https://doi.org/10.2967/jnumed.123.265703
You have access
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy
Surekha Yadav, Courtney Lawhn-Heath, Alan Paciorek, Sheila Lindsay, Rebecca Mirro, Emily K. Bergsland and Thomas A. Hope

Journal of Nuclear Medicine March 1, 2024, 65 (3) 409-415; DOI: https://doi.org/10.2967/jnumed.123.266614
You have access
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
Laure Al Mansour, Louis De Mestier, Magalie Haissaguerre, Pauline Afchain, Julien Hadoux, Thierry Lecomte, David Morland, Anne Segolene Cottereau, Ophelie De Rycke, Ghoufrane Tlili, Jérémie Tordo, Marc Janier, Agathe Deville and Thomas Walter

Journal of Nuclear Medicine February 1, 2024, 65 (2) 258-263; DOI: https://doi.org/10.2967/jnumed.123.266063
You have access
Impact of Single-Time-Point Estimates of ¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J. Gross, Simona Grozinsky-Glasberg and Simona Ben-Haim

Journal of Nuclear Medicine October 1, 2023, 64 (10) 1610-1616; DOI: https://doi.org/10.2967/jnumed.122.264923
You have access
Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
Michael C. Bellavia, Ravi B. Patel and Carolyn J. Anderson

Journal of Nuclear Medicine November 1, 2022, 63 (11) 1636-1641; DOI: https://doi.org/10.2967/jnumed.122.264373

Main menu

User menu

Search

177Lu-DOTATATE

Pages